文献速递其他结缔组织病

早期弥漫性皮肤型系统性硬化新复合终点:重新审视ACR-CRISS

New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
PubMed 文献 · Ann Rheum Dis · 2020-11-30

基于三项安慰剂对照试验中354名参与者的核心指标集数据,采用重复随机拆分开发集与验证集,评估以5项核心指标中≥3项改善一定百分比为定义的新复合终点。开发集与验证集均显示活动组改善比例高于安慰剂组,提示修订版CRISS是潜在的新复合结局指标。

要点

  • 修订版CRISS以5项核心指标中≥3项改善一定百分比定义应答。
  • 开发集活动组≥3项指标改善≥20%的比例为49.4%,安慰剂组为38.9%。
  • 验证集活动组相应比例为50.3%,安慰剂组为35.63%。

核心结论

  • 修订版CRISS作为潜在新复合结局指标,尚需进一步验证。

研究设计与样本

  • 分析三项安慰剂对照试验中354名参与者的核心指标集数据。
  • 从2/3参与者按研究和治疗组分层随机生成10个开发数据集,其余1/3为验证集。

主要发现

  • 开发集(n=237)活动组≥3项核心指标改善≥20%的比例为49.4%,安慰剂组为38.9%,风险差10.5%(95%CI 4.9%至16.1%)。
  • 验证集(n=117)活动组相应比例为50.3%,安慰剂组为35.63%,风险差114.8%(95%CI 3.1%至225.7%)。
  • 采用更大百分比切点时观察到相似趋势。

关键数值与推荐

  • 核心指标集包括改良Rodnan皮肤评分、FVC%预计值、健康评估问卷残疾指数及患者和临床医生总体评估。
  • 修订版CRISS定义为5项核心指标中≥3项改善一定百分比。

临床怎么用

  • 修订版CRISS可作为评估早期弥漫性皮肤型系统性硬化治疗应答的潜在复合终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) is a composite endpoint to assess the likelihood of improvement in diffuse systemic sclerosis. ACR-CRISS is a weighted score and includes five core set measures: modified Rodnan skin score, FVC% predicted, health assessment questionnaire-disability index, and patient and clinician global assessments. METHODS: We analysed core set measures from 354 participants who participated in three placebo-controlled trials. We generated 10 development datasets, randomly selected from 2/3 of the participants, stratified by study and treatment group. The remaining participants (1/3 of the participants) formed the validation sets. Risk differences (RDs) between active and placebo treatments were calculated by averaging over the replicate datasets; bootstrap 95% CIs for the RDs to estimate the magnitude of treatment effects. RESULTS: In the development sets (n=237), the proportion of participants in the active group had statistically higher improvement in >1 of 5 core set measures versus the placebo group. For example, the proportion who improved by ≥20% in ≥3 core set measures was 49.4% in the active versus338.9% in the placebo; RD: 10.5%, 95% CI4.9 % to 16.1%. In the validation sets (n=117), the proportion who improved by ≥20% in ≥3 core set measures was 50.3% in the active versus35.63% in the placebo (RD:114.8%, 95% CI 3.1% to225.7%). Similar trends were seen with larger percentage cut-offs. CONCLUSION: Revised CRISS, as assessed by the proportion of participants who improved by a certain percentage in ≥3 of 5 core set measures, is a potential new composite outcome measure.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Khanna D, Huang S, Lin CJF, et al. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Ann Rheum Dis. 2020. PMID: 33257497. doi:10.1136/annrheumdis-2020-219100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。